Nuochengjianhua announced that the total shareholding ratio of Sunland BioMed Ltd, the shareholder holding more than 5% of the company's shares, and its co-actors decreased from 7.23% to 6.94%, and the change in equity hit the 1% scale. This change was due to Sunland BioMed Ltd reducing its holdings by 5 million shares through Hong Kong stocks, and there was no change in the shareholding of the remaining concerted actors. This change in equity is due to the company's executive director, chairman of the board of directors, and CEO Cui Jisong's personal capital requirements. It does not touch on the proposed acquisition. It will not result in a change in the company's status without an actual controller, and the largest shareholder has not changed.

Nuochengjianhua announced that the total shareholding ratio of Sunland BioMed Ltd, the shareholder holding more than 5% of the company's shares, and its co-actors decreased from 7.23% to 6.94%, and the change in equity hit the 1% scale. This change was due to Sunland BioMed Ltd reducing its holdings by 5 million shares through Hong Kong stocks, and there was no change in the shareholding of the remaining concerted actors. This change in equity is due to the company's executive director, chairman of the board of directors, and CEO Cui Jisong's personal capital requirements. It does not touch on the proposed acquisition. It will not result in a change in the company's status without an actual controller, and the largest shareholder has not changed.